Stock Under $10 with 50-100% upside potential - 14 Days FREE!

Double-digit Growth Rate Of The Pharmaceuticals Industry In Asia Pacific Boosts The API Market, Finds Frost & Sullivan





SINGAPORE, Dec. 4, 2012 /PRNewswire/ -- The pharmaceuticals industry in the Asia Pacific is thriving on the back of escalating population and increasing incidence of lifestyle diseases.. Its success has a direct bearing on the region's active pharmaceutical ingredients (API) market, which is drawing considerable attention from foreign investors.

New analysis from Frost & Sullivan ( http://www.chemicals.frost.com), Analysis of the Active Pharmaceutical Ingredients Market, finds that the market earned revenues of $1.12 billion in 2011 and estimates this to reach $1.79 billion in 2018.

"The focus on healthcare has enabled Australasia to corner a large share of the global pharmaceuticals market, compelling market majors to train their spotlight on emerging countries," said Frost & Sullivan Research Analyst Tridisha Goswami. "This bodes well for the regional API market, as pharmaceutical companies' checklist for contract manufacturing includes low cost of production, and favorable geographic locations."

Labor costs are low in countries such as Vietnam, Indonesia, and Malaysia, making API contract manufacturing feasible in these countries. However, the limited resources and lack of technologies tarnish their attractiveness. Further, China and India, with their better developed contract manufacturing market, pose stiff competition to these countries; the higher influx of generic drugs drives volume demand but curbs revenue growth. This is majorly due to the high prices of innovative drugs, which gives a major boosts to API revenues.

Market participants can gain investors' confidence by focusing on quality and therapeutic applications in cancer and lifestyle-mediated diseases. The increasing focus on biological API in treating cancer and immune-mediated diseases will also bolster the market and cause a shift in pharmaceutical companies' preference from synthetic to biological API.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Dividend Stock Advisor
TRY IT FREE
New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Real Money
TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:
  • Jim Cramer + 20 Wall Street pros
  • Intraday commentary & news
  • Real-time trading forum
  • Actionable trade ideas
Real Money Pro
TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass + 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 15,354.40 121.18 0.80%
NASDAQ 3,498.97 33.73 0.97%
S&P 500 1,667.47 17.00 1.03%
US 10 Yr 1.949% +0.084

Brokerage Partners

Advertising Partners
Special Features

Free Newsletters from TheStreet

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy. Manage Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs